Want to see JP:6568 full AI Analyst Report?
Top Page
KNC Laboratories Co.,Ltd.
(6568)
Select Model
Select Model
Rating:57Neutral
Price Target:
¥1,366.00
▲(21.53% Upside)
Action:Reiterated
Date:05/16/26
The score is held back primarily by weakened profitability versus 2023–2024 and negative free cash flow in the last two years, despite a strong balance sheet. Technicals are also soft with the stock trading below key short-to-medium-term averages and weak momentum. Offsetting factors include the return to revenue growth and a reasonable valuation supported by a moderate dividend yield.
Positive Factors
Revenue Recovery
A renewed top-line recovery (11.2% YoY in 2026) signals recovering demand and restores scale economics. Over 2–6 months this supports better capacity utilization, steadier customer relationships and provides a foundation for margin repair if cost and pricing actions follow.
Negative Factors
Profitability Compression
Significant margin deterioration versus the 2023–2024 peak—gross profit fell in 2026 despite higher sales—suggests structural pressure from input costs, pricing or mix. Persisting compression undermines sustainable earnings power and limits capacity to rebuild reserves.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Recovery
A renewed top-line recovery (11.2% YoY in 2026) signals recovering demand and restores scale economics. Over 2–6 months this supports better capacity utilization, steadier customer relationships and provides a foundation for margin repair if cost and pricing actions follow.
Read all positive factors
KNC Laboratories Co.,Ltd. (6568) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥10.08B
Dividend Yield2.98%
Average Volume (3M)2.89K
Price to Earnings (P/E)13.1
Beta (1Y)0.57
Revenue Growth11.18%
EPS Growth3.75%
CountryJP
Employees340
SectorGeneral
Sector StrengthN/A
IndustryChemicals
Share Statistics
EPS (TTM)85.36
Shares Outstanding7,779,900
10 Day Avg. Volume3,150
30 Day Avg. Volume2,890
Financial Highlights & Ratios
PEG Ratio3.29
Price to Book (P/B)0.67
Price to Sales (P/S)1.04
P/FCF Ratio-26.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)208.6
Revenue Forecast (FY)¥12.00B
KNC Laboratories Co.,Ltd. Business Overview & Revenue Model
Company Description
KNC Laboratories Co., Ltd. engages in research, development, and production solutions for organic chemicals. Its operations are carried out through the following business divisions: Functional Materials Business, Pharmaceutical Business, and Bio B...
How the Company Makes Money
null...
KNC Laboratories Co.,Ltd. Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
74
Positive
Cash Flow
46
Neutral
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 9.09B | 8.18B | 9.15B | 8.63B | 7.44B |
| Gross Profit | 2.39B | 2.27B | 3.24B | 3.26B | 2.06B |
| EBITDA | 2.29B | 1.83B | 3.02B | 3.10B | 1.86B |
| Net Income | 766.20M | 737.33M | 1.49B | 1.54B | 643.46M |
Balance Sheet | |||||
| Total Assets | 21.64B | 20.20B | 18.71B | 15.47B | 14.03B |
| Cash, Cash Equivalents and Short-Term Investments | 2.17B | 2.39B | 3.31B | 2.30B | 1.97B |
| Total Debt | 3.60B | 3.12B | 1.97B | 1.54B | 1.68B |
| Total Liabilities | 7.56B | 6.68B | 5.62B | 3.73B | 3.46B |
| Stockholders Equity | 14.08B | 13.52B | 13.09B | 11.75B | 10.58B |
Cash Flow | |||||
| Free Cash Flow | -363.52M | -1.82B | 850.16M | 863.73M | -248.27M |
| Operating Cash Flow | 2.26B | 1.49B | 3.20B | 1.99B | 585.11M |
| Investing Cash Flow | -2.70B | -3.32B | -2.37B | -1.15B | -613.51M |
| Financing Cash Flow | 222.35M | 909.60M | 178.87M | -523.39M | 39.02M |
KNC Laboratories Co.,Ltd. Technical Analysis
Positive
1124.00
Price Trends
1267.58
Positive
1257.72
Positive
1200.03
Positive
Market Momentum
16.57
Positive
55.01
Neutral
47.51
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:6568, the sentiment is Positive. The current price of 1124 is below the 20-day moving average (MA) of 1322.25, below the 50-day MA of 1267.58, and below the 200-day MA of 1200.03, indicating a neutral trend. The MACD of 16.57 indicates Positive momentum. The RSI at 55.01 is Neutral, neither overbought nor oversold. The STOCH value of 47.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:6568.
KNC Laboratories Co.,Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | ¥7.20B | 8.71 | ― | 1.93% | 18.15% | ― | |
65 Neutral | ¥7.70B | 24.33 | ― | 2.97% | 2.12% | -64.98% | |
63 Neutral | ¥15.31B | 18.20 | ― | 1.81% | 4.46% | -3.54% | |
57 Neutral | ¥10.08B | 13.09 | ― | 2.98% | 11.18% | 3.75% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
43 Neutral | ¥8.60B | 28.58 | ― | 1.06% | -7.88% | 129.19% |
* General Sector Average
JP:6568
KNC Laboratories Co.,Ltd.
1,296.00
230.45
21.63%
JP:4360
MANAC Chemical Partners Co.,Ltd
835.00
333.05
66.35%
JP:4366
Daito Chemix Corporation
462.00
230.15
99.27%
JP:4531
Yuki Gosei Kogyo Co., Ltd.
353.00
99.42
39.21%
JP:4960
Chemipro Kasei Kaisya,Ltd.
523.00
255.02
95.16%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.